How can we give patients faster access to innovative treatments and cures? That’s the question being asked of our nation’s foremost medical experts and innovators by members of the House of Representatives’ Energy and Commerce Committee through an initiative called “21st Century Cures.”
Alzheimer’s is one area that represents a tsunami of public health challenges confronting us, and therefore must rise to the top of this timely discussion. Without intervention or prevention to delay or slow Alzheimer’s progression in patients, or the discovery of a cure, the disease will overwhelm the healthcare system within the next 25-30 years.
The financial cost to the U.S. healthcare system of caring for individuals with the disease is estimated at over $200 million today and will rise to over $1 trillion by 2050.
The societal costs are inestimable. These predictions do not include individuals with early-onset of the disease, who are under the age of 65 at first onset or diagnosis.
Something must be done.
I believe there are three key steps that will help expedite the development of cures and treatments:
- Collaborate by forming public-private partnerships and coordinating efforts with existing initiatives;
- Collect health care data, genomic data, and biospecimens to identify potential risk factors, causes, biomarkers and targets for intervention; and
- Communicate the outcomes of the study publicly to translate the results into treatments and, potentially, a cure.
I propose the development and execution of a large-scale, longitudinal study to sequence the genomes of 100,000 volunteers in age cohorts from those in their 20s through those in their 80s, obtain biospecimens and additional health care data from those individuals, and develop biological markers that may predict Alzheimer’s or other chronic diseases for which the cause is unknown or poorly understood.
This large-scale, long-range study will not only yield data necessary to find ways to cure and prevent Alzheimer’s, it would help researchers find ways to treat hundreds of other diseases for which we still lack adequate therapies.
There is broad agreement that advancements in biologic and drug development will best be accomplished through collaborations that bring together knowledge, skills, and expertise, as well as funding, from the public and private sectors.
Public and private entities worldwide are engaged in efforts to understand the disease, to determine how best to develop therapies, and to address the enormous challenges facing caregivers. Such partnerships and consortia already are making progress in a number of areas with high public health impact, including Alzheimer’s.
These multiple efforts need to be coordinated effectively for the greatest possibility of realizing a return on investment that expedites prevention of the impending Alzheimer’s crisis.
It is well recognized that a first step toward a cure is to identify the cause of the disease, individuals who are at risk for the disease, and potential targets for intervention.
Our hopes for cures hinge on understanding how to intervene to halt the disease’s progress. Through this proposed study, we would identify precursors and early signs of disease or disease risk. This information could be made publicly available so drug and device developers would have defined targets and potentially could develop ways to prevent and treat the disease.
The urgency of finding a cure for Alzheimer’s cannot be overstated. It is difficult to find anyone whose life has not been affected by this devastating disease. Biotech holds the greatest promise for finding a cure. We must act now for the patients and their families who are counting on us.
Greenwood is president and CEO of the Biotechnology Industry Organization.